Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors

Published:2020-07 Issue:10 Volume:12 Page:675-679
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Vici Patrizia¹^ORCID,Pizzuti Laura¹^ORCID,Krasniqi Eriseld¹^ORCID,Botticelli Andrea²^ORCID,Ciliberto Gennaro³^ORCID,Barba Maddalena¹^ORCID

Affiliation:

1. Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy

2. Department of Clinical & Molecular Oncology, University of Rome “Sapienza”, Rome, Italy

3. Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2020-0142

Reference42 articles.

1. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed

2. PD-1/PD-L1 Pathway in Breast Cancer

3. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses

4. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

5. PD-L2 is a second ligand for PD-1 and inhibits T cell activation

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection;Cancers;2021-01-15

2. Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection;Cancers;2020-11-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3